China has been experiencing an increase in cases of influenza-like illnesses compared with the same period in the previous three years when strict measures were in force as part of its zero-COVID strategy.
The WHO noted that China’s National Health Commission told a press conference earlier this month that there had been an increase in the incidence of respiratory diseases, attributing them to the lifting of COVID-19 measures and the spread not only of COVID-19 but pathogens such as influenza, mycoplasma pneumoniae (a common bacterial infection which typically affects younger children), and respiratory syncytial virus (RSV).
The health (COVIRIX) IPO must be close now..
"We are starting to see a much stronger level of interest among healthcare experts and the community in seeking alternative antivirals to Paxlovid by Pfizer, and Molnupiravir by Merck as effective treatments without the side effects of these existing antivirals on the market. Vaccination has also to date failed to stop infections or the spread of infections. With the recent surges in a number of respiratory diseases, the COVIRIX Medical team has decided to expand the scope of its antiviral applications to investigate the application of its patented antiviral treatment for a wider range of respiratory diseases including Covid. Due to its unique mechanism of action and being broad spectrum, COVIRIX Medical believes its same patented antiviral treatment is likely to be applicable in treating a wide range of viral respiratory diseases for example and including"
